期刊
JOURNAL OF LIPID RESEARCH
卷 58, 期 2, 页码 403-411出版社
ELSEVIER
DOI: 10.1194/jlr.M072751
关键词
magnetic resonance imaging; cholesterol; brain atrophy
资金
- National Multiple Sclerosis Society [RG4836-A-5]
- Ministry of Health of the Czech Republic [PRVOUK-P26/LF1/4, RVO-VFN64165, NT13237-4/2012, NT13108-4/2012]
The purpose of this work was to determine whether changes in cholesterol profiles after interferon- (IFN-)1a treatment initiation following the first demyelinating event suggestive of multiple sclerosis are associated with clinical and MRI outcomes over 4 years. A group of 131 patients (age: 27.9 +/- 7.8 years, 63% female) with serial 3-monthly clinical and 12-monthly MRI follow-ups over 4 years were investigated. Serum cholesterol profiles, including total cholesterol (TC), HDL cholesterol (HDL-C), and LDL cholesterol (LDL-C) were obtained at baseline, 1 month, 3 months, and every 6 months thereafter. IFN-1a initiation caused rapid decreases in serum HDL-C, LDL-C, and TC within 1 month of IFN-1a initiation (all P < 0.001) that returned slowly toward baseline. In predictive mixed model analyses, greater percent decreases in HDL-C after 3 months of IFN-1a treatment initiation were associated with less brain atrophy over the 4 year time course, as assessed by percent brain volume change (P < 0.001), percent gray matter volume change (P < 0.001), and percent lateral ventricle volume change (P = 0.005). Decreases in cholesterol biomarkers following IFN-1a treatment are associated with brain atrophy outcomes over 4 years. Pharmacological interventions targeting lipid homeostasis may be clinically beneficial for disrupting neurodegenerative processes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据